Evoke Pharma

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

LOS ANGELES--(BUSINESS WIRE)--InvestCloud, a global leader in wealth technology, announced a strategic partnership with Registered Investment Adviser (RIA) Evoke Advisors (Evoke) to transform their digital experience. With InvestCloud's Client Experience, Evoke's clients, prospects, and third-party intermediaries will benefit from a significantly elevated and differentiated branded experience that features powerful, data-driven visualizations catering to the firm's exclusive clientele. As the t.

InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Entain PLC

Shares in bookmakers galloped higher after the UK Budget, led by Ladbrokes and Coral owner Entain PLC (LSE:ENT), which rose over 8%, and William Hill owner Evoke PLC, rising 12%. Paddy Power and Betfair owner Flutter Entertainment PLC (LSE:FLTR) also rose 6%.

Ladbrokes and William Hill owners Entain and Evoke jump on Budget relief

Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its metoclopramide nasal spray.   The pharmaceutical company said its nasal spray known broadly as GIMOTI offers substantial benefits to patients of diabetic gastroparesis (DGP) on GLP-1 receptor agonists.

Evoke Pharma stock surges over 100%—here's why

SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held from October 25-29, 2024.

Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting

SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024.   This appointment fulfills a condition set as part of the company's most recent financing by Nantahala Capital Management.

Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

William Hill and 888 owner Evoke PLC (LSE:EVOK) has reported a 3% increase in revenue to £417 million for the third quarter of 2024, compared to the same period last year. It highlighted that this marks its first quarter of year-on-year growth since Q1 2022, and its progress was driven by market share gains in key international markets.

Evoke reports first quarter of growth in over two years

Flutter Entertainment PLC

Shares in listed bookmakers Entain PLC (LSE:ENT), Flutter Entertainment PLC (LSE:FLTR) and Evoke PLC (LSE:EVOK) tumbled on the back of news that the UK government might target the sector in this month's Budget.  HM Treasury could hit the gambling industry with a £3 billion tax raid, it was reported at the weekend, as Rachel Reeves looks for ways to help fill the £22 billion 'black hole' in the public finances.

Bookmakers Entain, Flutter, Evoke and Rank tumble on new gambling tax reports

Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants.

Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

SAN DIEGO--(BUSINESS WIRE)-- #CleanTech--EVoke Partnership.

XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry

SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the Gastroenterology and Hepatology Advanced Practice Providers Conference taking place from September 12 – 14, 2024 at the Gaylord National Resort Convention Center in National Harbor, Maryland.

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9 – 11, 2024 at the Lotte New York Palace Hotel in New York City.

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

William Hill owner Evoke plc reported a 2.2% year-over-year decrease in revenue for the first half of 2024, amounting to £862 million. The company also saw a significant drop in adjusted EBITDA, which fell by 25.8% to £115.5 million.

William Hill owner Evoke's losses escalate

GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA™, a leading provider of global commercial services to the life science industry, joins the gastroparesis community in recognizing Gastroparesis Awareness Month throughout August and supporting the millions of people living with gastroparesis or suffering from associated symptoms of the condition.

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its board of directors (Board) has approved a 1-for-12 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on August 1, 2024. The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the same symbol (EVOK) when the market opens on August 1, 2024 with the new CUSIP number 30049G302.

Evoke Pharma, Inc. Announces Reverse Stock Split

Shares in Evoke PLC fell almost 9% after the William Hill owner warned that first-half profits would come in below expectations. Adjusted EBITDA for the first six months of the year are now guided to be around £35-40 million "behind plan", with full-year results also likely to be hit too.

William Hill owner Evoke tumbles after issuing profit warning

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy.

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C.

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company's $14M net revenue guidance for 2024

Evoke Pharma Reports First Quarter 2024 Financial Results

Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer.

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022

News for Evoke Pharma Stock (EVOK)